All stock lists
Syndax Pharmaceuticals Inc (NASDAQ:SNDX)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
13.65-0.50 (-3.53%)
Market cap
$1.22B
Insider Score
Health Score
Analyst consensus
Listed since
Mar 2, 2016
Website
Insider Score
––Not scored
SNDX Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
SNDX analyst forecast
SNDX analyst consensus
Moderate Buy3 ratings
Buy 3 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
SNDX 12-month price target
$34.33+151.5% upsideaverage of 6 firms
$45.00High
$22.00Low
SNDX ratings mix, last 12 months
Buy Hold Sell
Best analysts covering SNDX
- UBS100%success rate · +155.4% avg return · 1 call
- BTIG75%success rate · +18.8% avg return · 4 calls
- Citigroup63%success rate · +7.8% avg return · 8 calls
- JP Morgan50%success rate · +6.4% avg return · 10 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
SNDX analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-10-13 |
| Jefferies | — | $35.00 | +96.0% | — | 2026-09-29 | |
| UBS | Buy | $33.00 | +67.1% | Reiterated | 2026-08-21 | |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-08-11 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-08-05 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-07-15 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-06-12 |
| Guggenheim | — | $31.00 | +73.1% | — | 2026-06-12 | |
| H.C. Wainwright | — | $40.00 | +117.5% | — | 2026-06-03 | |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-05-22 |
| — | UBS | Buy | — | — | Reiterated | 2026-05-13 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-05-01 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2026-04-01 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-03-31 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-03-09 |
| — | Citigroup | Buy | — | — | Reiterated | 2026-03-02 |
| Stifel Nicolaus | — | $45.00 | +107.3% | — | 2026-02-27 | |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-01-27 |
| — | BTIG | Buy | — | — | Reiterated | 2025-12-09 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-11-24 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-11-12 |
| Barclays | Overweight | $22.00 | +59.9% | Reiterated | 2025-11-04 | |
| — | UBS | Buy | — | — | Reiterated | 2025-11-04 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-10-27 |
| — | BTIG | Buy | — | — | Reiterated | 2025-10-27 |
| — | BTIG | Buy | — | — | Reiterated | 2025-09-19 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2025-09-05 |
| — | Citigroup | Buy | — | — | Reiterated | 2025-08-05 |
| — | BTIG | Buy | — | — | Reiterated | 2025-08-05 |
| UBS | Buy | $35.00 | +257.3% | Reiterated | 2025-07-15 | |
| Goldman Sachs | — | $18.00 | +83.3% | — | 2025-07-10 | |
| — | Scotiabank | Sector Perform | — | — | Reiterated | 2025-05-06 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-05-06 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-03-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-03-04 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-03-04 |
| — | Citigroup | Buy | — | — | Reiterated | 2025-03-04 |
| — | Scotiabank | Sector Perform | — | — | Reiterated | 2025-01-08 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-12-10 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2024-11-21 |
| — | Citigroup | Buy | — | — | Reiterated | 2024-11-19 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-18 |
| Scotiabank | — | $18.00 | -10.2% | — | 2024-11-13 | |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-12 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2024-11-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-06 |
| UBS | — | $37.00 | +99.6% | — | 2024-10-24 | |
| — | Stifel | Buy | — | — | Reiterated | 2024-10-14 |
| Citigroup | Buy | $34.00 | +69.2% | Reiterated | 2024-08-16 | |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-15 |
| — | B of A Securities | Buy | — | — | Reiterated | 2024-08-15 |
| Barclays | Overweight | $33.00 | +68.5% | Reiterated | 2024-08-15 | |
| Bank of America Securities | — | $31.00 | +58.3% | — | 2024-08-15 | |
| — | JP Morgan | Overweight | — | — | Reiterated | 2024-08-06 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-02 |
| — | B of A Securities | Buy | — | — | Reiterated | 2024-07-30 |
| Bank of America Securities | — | $30.00 | +36.4% | — | 2024-07-30 | |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-07-29 |
| Jefferies | — | $37.00 | +82.1% | — | 2024-06-28 |
SNDX earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2025-11-03 | -0.74 | -0.70 | $63.3M | $45.9M |
| 2026-02-26 | -0.58 | -0.78 | $64.3M | $68.7M |
| 2026-04-30 | -0.59 | -0.48 | $69.8M | $64.9M |
| 2026-08-04 | -0.45 | -0.55 | $79.4M | $72.8M |
| 2026-11-02Upcoming | -0.49 | — | $81.7M | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.